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OBJECTIVE — To examine the relationship between plasma IGF-1 and interleukin-6 (IL-6)
levels in Caucasian nondiabetic subjects and evaluate the association of IGF-1 and IL-6 with the
cardiometabolic risk factors characterizing metabolic syndrome (MetS).
RESEARCH DESIGN AND METHODS — The study group consisted of 186 Caucasian
nondiabetic subjects who underwent an oral glucose tolerance test and an euglycemic-
hyperinsulinemic clamp. A logistic regression analysis, adjusted for age and sex, was used to
determine the association between tertiles of IGF-1 and IL-6 and the MetS and its compo-
nents.
RESULTS — After adjusting for age and sex, both IGF-1 and IL-6 were correlated with
insulin resistance and individual components of MetS, but in opposite directions. In the
logistic regression model adjusted for age and sex, higher IL-6 and lower IGF-1 levels confer
increased risk of having MetS and its two underlying pathophysiological abnormalities, i.e.,
visceral obesity and insulin resistance.
CONCLUSIONS — The present results raise the possibility that lowered protection
against inﬂammation, i.e., lower IGF-1 levels, may have a role in the development of MetS
and its features, resulting in an imbalance between proinﬂammatory and anti-inﬂammatory
proteins.
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M
etabolic syndrome (MetS) is a
condition characterized by a clus-
tering of interrelated cardiometa-
bolic risk factors and is associated with
increased risk for both type 2 diabetes
and atherosclerotic cardiovascular dis-
ease (1,2). Visceral obesity and insulin
resistance are considered central to the
pathophysiology of MetS. Growing evi-
dencesuggestsalinkbetweenalow-grade
inﬂammatory state and MetS (1,2). With
increased visceral adiposity, proinﬂam-
matory cytokine production is enhanced,
causing insulin resistance. MetS is associ-
ated with abnormalities in the growth
hormone/IGF-1 axis, resulting in low
plasma IGF-1 levels (3). IGF-1 has anti-
inﬂammatory effects and decreases ex-
pression of proinﬂammatory cytokines
such as interleukin-6 (IL-6) (4). There is
also evidence in animal models that IL-6
decreases circulating IGF-1 levels (5),
suggesting that an unpaired balance be-
tween proinﬂammatory and anti-
inﬂammatory cytokines may have a role
in the development of MetS. The aim of
thisstudywastoexaminetherelationship
betweenplasmaIGF-1andIL-6levelsina
cohort of nondiabetic subjects and to
evaluatetheassociationofIGF-1andIL-6
with the cardiometabolic risk factors
characterizing MetS.
RESEARCH DESIGN AND
METHODS—The study group con-
sisted of 186 Caucasian nondiabetic sub-
jects participating in the CAtanzaro
MEtabolic RIsk factors Study
(CATAMERIS), a metabolic disease pre-
vention campaign for cardiometabolic
risk factors (6). After 12-h fasting, sub-
jects underwent an oral glucose tolerance
test and a euglycemic-hyperinsulinemic
clamp, as previously described (6).
Whole-body glucose disposal (WBGD)
was calculated as reported (6). Insulin re-
sistance was also estimated by homeosta-
sis model assessment (HOMA). MetS was
deﬁned according to American Heart As-
sociation and National Heart, Lung, and
BloodInstitutecriteria.Thestudywasap-
proved by the institutional ethics com-
mittees,andwrittenconsentwasobtained
from all participants. Variables with
skeweddistributionwerelogtransformed
for analyses. Pearson’s correlation coefﬁ-
cients were used to compute correlations
between variables. A logistic regression
analysis was used to determine the asso-
ciation between the tertiles of IGF-1 or
IL-6andtheMetSanditsindividualcom-
ponents. Relationships between variables
were sought by multivariate linear regres-
sion analysis to assess the magnitude of
their effect on WBGD.
RESULTS—Anthropometric and bio-
chemical characteristics of the study sub-
jectsareshowninTable1.Afteradjusting
for sex and age, IGF-1 levels were nega-
tively correlated with BMI, waist circum-
ference, systolic blood pressure,
triglycerides, fasting insulin, and HOMA
andpositivelycorrelatedwithWBGD.Af-
ter adjusting for age and sex, IL-6 levels
werepositivelycorrelatedwithBMI,waist
circumference, systolic blood pressure,
fastinginsulin,andHOMAandnegatively
correlated with WBGD and IGF-1 levels.
In a logistic regression model adjusted for
age and sex, IGF-1 in the lowest tertile
(135 ng/ml) was associated with an in-
creased risk of having MetS (odds ratio
[OR] 3.07 [95% CI 1.2–7.9]), low HDL
choldesterol (3.15, [1.2–8.1]), and larger
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compared with the highest tertile (221
ng/ml). After adjusting for age, sex, and
lipidlevels,IGF-1inthelowesttertilewas
associated with increased risk of insulin
resistance, i.e., the highest HOMA tertile
(3.08, [1.2–7.6]) or lowest WBGD tertile
(3.31, [1.01–10.9]). Conversely, in a lo-
gistic regression model adjusted for age
and sex, IL-6 in the highest tertile (2.5
pg/ml) was associated with an increased
riskofhavingMetS(3.21[1.2–8.1]),high
blood pressure (2.63 [1.1–6.4]), and
larger waist circumference (4.42 [1.8–
11.0]) compared with the lowest tertile
(1.3pg/ml).Afteradjustingforage,sex,
and lipid levels, IL-6 in the highest tertile
was associated with increased risk of in-
sulin resistance, i.e., the highest HOMA
tertile (2.14, [1.01–5.31]) or lowest
WBGD tertile (4.64, [1.5–14.1]). To esti-
mate the independent contribution of
variables to WBGD, we carried out a mul-
tivariateregressionanalysisinamodelin-
cluding age, sex, BMI, waist
circumference,triglycerides,HDLcholes-
terol, IL-6, IGF-1, and fasting and 2-h
postchallenge glucose levels. The four
variablesthatremainedsigniﬁcantlyasso-
ciated with WBGD were age (P  0.01),
waistcircumference(P0.01),2-hpost-
challenge glucose (P  0.001), and IL-6
(P  0.04), accounting for 61.2% of its
variation.
CONCLUSIONS—In this study, we
report an inverse relationship between
plasma IGF-1 and IL-6 levels consistent
with clinical (7) and experimental data
showing that IGF-1 acts as an anti-
inﬂammatory molecule inhibiting IL-6
expression (4) and that IL-6 decreases
IGF-I levels by increasing its clearance
(5). Both IGF-1 and IL-6 are associated
withMetSanditsindividualcomponents,
but in opposite directions. Higher IL-6
and lower IGF-1 levels confer increased
risk of having MetS and its two underly-
ing pathophysiological abnormalities,
i.e., visceral obesity and insulin resis-
tance. Interestingly, multivariate regres-
sion analysis showed that IL-6 but not
IGF-1 levels were independently associ-
ated with WBGD. These results raise the
possibility that proinﬂammatory mole-
cules may have a more important role
than anti-inﬂammatory proteins in the
development of insulin resistance and
MetS. This study has some limitations:
ﬁrst, its cross-sectional nature makes it
impossible to draw any conclusions on
causality. Furthermore, while increasing
evidence supports the concept that a low-
grade proinﬂammatory state associated
with increased visceral adiposity may in-
duce insulin resistance and hence MetS
(1), it has been recently demonstrated (8)
thatacuteIL-6exposuredirectlyincreases
glucose metabolismin intact human skel-














Sex (M/F) 80/106 — — — —
Age (years) 41  14 0.53* 0.0001 0.30* 0.0001
BMI (kg/m
2) 30.1  8.4 0.28 0.0001 0.33 0.0001
Waist circumference (cm) 97  16 0.29 0.0001 0.35 0.0001
SBP (mmHg) 127  19 0.15 0.04 0.15 0.04
DBP (mmHg) 80  11 0.10 0.18 0.13 0.08
Total Cholesterol (mg/dl) 198  41 0.03 0.66 0.006 0.95
HDL Cholesterol (mg/dl) 54  14 0.11 0.11 0.07 0.33
Triglyceride (mg/dl) 121  69 0.19 0.01 0.10 0.15
Fasting Glucose (mgl/dl) 90  14 0.03 0.63 0.007 0.93
2-h glucose (mg/dl) 117  39 0.07 0.42 0.13 0.11
Fasting Insulin (U/ml) 12  7 0.16 0.03 0.28 0.0001
IGF-1 (ng/ml) 191  90 — — 0.15 0.04
IL-6 (pg/ml) 2.5  2.2 0.15 0.04 — —
HOMA 2.7  1.8 0.21 0.004 0.22 0.002
WBGD (mg · kg
1 · min
1) 7.6  3.2 0.29 0.002 0.35 0.0001
AHA-NHLB–deﬁned metabolic syndrome (yes/no) 60/126 (32.3) — — — —
High waist circumference (102 cm for men and
88 cm for women) (yes/no)
91/95 (48.9) — — — —
High fasting glucose (100 mg/dl) (yes/no) 47/139 (25.3) — — — —
High triglyceride (150 mg/dl l) (yes/no) 50/136 (26.8) — — — —
Low HDL (40 mg/dl in men or 50 mg/dl in
women) (yes/no)
54/132 (29.0) — — — —
High blood pressure (SBP 130 mmHg or DBP
85 mmHg) (yes/no)
101/85 (54.6) — — — —
Data are means  SD and n (%). Fasting plasma insulin, triglycerides, and IL-6 levels were log transformed for statistical analysis, but values in the table represent
a back transformation to the original scale. DBP, diastolic blood pressure; SBP, systolic blood pressure. *Adjusted for sex.
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sion of the possibility that increased IL-6
levels in our population may represent an
attempt to counteract insulin resistance
by increasing glucose transport. How-
ever, it has also been observed (9) that
reduced IGF-1 levels are protective and
associatedwithprolongedlifespanincen-
tenarians, and we cannot exclude that in
the study population decreased IGF-1
levels represent a reactive rather than a
causative state. This study should thus be
considered hypothesis generating and re-
quires further prospective investigations.
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